2013
The vesicular monoamine transporter (VMAT-2) inhibitor tetrabenazine induces tremulous jaw movements in rodents: Implications for pharmacological models of parkinsonian tremor
Podurgiel S, Nunes E, Yohn S, Barber J, Thompson A, Milligan M, Lee C, López-Cruz L, Pardo M, Valverde O, Lendent C, Baqi Y, Müller C, Correa M, Salamone J. The vesicular monoamine transporter (VMAT-2) inhibitor tetrabenazine induces tremulous jaw movements in rodents: Implications for pharmacological models of parkinsonian tremor. Neuroscience 2013, 250: 507-519. PMID: 23867769, DOI: 10.1016/j.neuroscience.2013.07.008.Peer-Reviewed Original ResearchMeSH KeywordsAdrenergic Uptake InhibitorsAnimalsCatalepsyData Interpretation, StatisticalDisease Models, AnimalDose-Response Relationship, DrugJawMaleMiceMice, KnockoutMotor ActivityMovementParkinsonian DisordersProto-Oncogene Proteins c-fosRatsRats, Sprague-DawleyReceptor, Adenosine A2ATetrabenazineTremorVesicular Monoamine Transport ProteinsXanthinesConceptsTremulous jaw movementsVentrolateral neostriatumC-fos expressionMSX-3Receptor transmissionAdenosine A2A antagonist MSX-3A2A receptor knockout miceParkinsonian tremorC-Fos-positive cellsAbility of tetrabenazineParkinsonian side effectsVesicular monoamine storageJaw movementsReceptor knockout miceAdenosine A2A receptorsOral tremorWild-type controlsPharmacological antagonismStriatal dopamineLocomotor suppressionMotor effectsCD1 miceRodent modelsKnockout miceSide effects
2012
The novel adenosine A2A antagonist prodrug MSX-4 is effective in animal models related to motivational and motor functions
Santerre J, Nunes E, Kovner R, Leser C, Randall P, Collins-Praino L, Cruz L, Correa M, Baqi Y, Müller C, Salamone J. The novel adenosine A2A antagonist prodrug MSX-4 is effective in animal models related to motivational and motor functions. Pharmacology Biochemistry And Behavior 2012, 102: 477-487. PMID: 22705392, DOI: 10.1016/j.pbb.2012.06.009.Peer-Reviewed Original ResearchConceptsMSX-3Amino acid ester prodrugsTreatment of depressionDorsal striatal functionDopamine D2 receptorsSame dose rangeNucleus accumbens coreEffort-related choice behaviorConcurrent leverOral tremorD2 antagonistIntraperitoneal administrationActive dosesLocomotor suppressionMotor functionStriatal functionD2 receptorsAnxiogenic effectsMotor impairmentSelective adenosineAnimal modelsMotivational symptomsAccumbens coreAntiparkinsonian profileEster prodrugs
2009
Intracerebroventricular administration of cannabinoid CB1 receptor antagonists AM251 and AM4113 fails to alter food-reinforced behavior in rats
Sink K, Segovia K, Nunes E, Collins L, Vemuri V, Thakur G, Makriyannis A, Salamone J. Intracerebroventricular administration of cannabinoid CB1 receptor antagonists AM251 and AM4113 fails to alter food-reinforced behavior in rats. Psychopharmacology 2009, 206: 223-232. PMID: 19588124, PMCID: PMC4425366, DOI: 10.1007/s00213-009-1602-8.Peer-Reviewed Original ResearchMeSH KeywordsAnalysis of VarianceAnimalsBehavior, AnimalConditioning, OperantDose-Response Relationship, DrugDrug Administration RoutesDrug InteractionsEatingFood DeprivationInjections, IntraventricularMaleMotor ActivityPiperidinesPyrazolesRatsRats, Sprague-DawleyReceptor, Cannabinoid, CB1Reinforcement ScheduleReinforcement, PsychologyConceptsFood-reinforced behaviorCB1 receptorsLocomotor suppressionFood-motivated behaviorCannabinoid CB1 receptorsCB1 neutral antagonistsSame dose rangeModulation of locomotionIntracerebroventricular administrationICV administrationLocus of actionLower brainstemReceptor transmissionPeripheral receptorsSystemic administrationLateral ventricleAppetite suppressantsNucleus accumbensAM251AM4113Inverse agonistNeutral antagonistsDose rangeAdministrationReceptors